 |
|
New study shows that therapeutic gene expression can be sustainable for 1 year
October 26, 2007May pave the way to more effective, long lasting, and safer gene therapy treatments
Researchers at the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have shown for the first time that it is possible to sustain therapeutic gene expression in the central nervous system for up to a year, even in the presence of an anti-viral immune response mechanism that is normally present in humans.
The researchers demonstrated in an animal model that the delivery system for the gene, a novel gutted adenoviral vector called HC-Adv, is completely invisible to the immune system. Vectors previously used to deliver genes carried minute amounts of viral proteins that were detected by the immune system, triggering an immune response that rendered the therapeutic gene inactive after a period of weeks.
According to the researchers, this delivery system is safer and more effective than what is currently available, and should therefore advance clinical gene therapy trials for people suffering from central nervous system disorders such as Parkinson's, Alzheimer's, and Multiple Sclerosis. The research was sponsored in part by The National Institutes of Health.
Cedars-Sinai Medical Center
According to the researchers, this delivery system is safer and more effective than what is currently available, and should therefore advance clinical gene therapy trials for people suffering from central nervous system disorders such as Parkinson's, Alzheimer's, and Multiple Sclerosis. The research was sponsored in part by The National Institutes of Health.
Cedars-Sinai Medical Center
More Therapeutic Gene Expression News Articles
| Sirna Therapeutics granted two key patents on its RNA interference technology.: An article from: BIOTECH Patent News This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on February 1, 2005. The length of the article is 818 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:... | |
 | Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms, Applications, and Therapeutic Implications In the post-genomic era we have, at our fingertips, an incredible array of genomic sequences from a multitude of complex organisms. There remains, however, the critical need to understand the precise roles individual genes play in complex biological milieu. Synthetic nucleic acids are at the cutting-edge of molecular strategies that target genes of interest in a specific, efficient and... |
| Gene expression may be 'therapeutic target' for stroke.(Neuropsychiatric Medicine): An article from: Clinical Psychiatry News by Betsy Bates This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on February 1, 2006. The length of the article is 515 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:... | |
| Signal Transduction Pathways, Chromatin Structure, And Gene Expression Mechanisms As Therapeutic Targets (Annals of the New York Academy of Sciences, V. 1030) | |
| Therapeutic Oligonucleotides: Transcriptional and translational Strategies for Silencing Gene Expression (Annals of the New York Academy of Sciences) by Cooley's Anemia Symposium 2005 Lake Buen, Elliott P. Vichinsky, NIH SYMPOSIUM ON THERAPEUTIC OLIGONUCLEO, Yoon S. Cho-Chung, Cy A. Stein | |
| New Frontiers in the Study of Gene Functions (New Horizons in Therapeutics) |
| © 2008 BrightSurf.com |